Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR #TumorTreatingFieldsTherapy--Novocure launched a campaign to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality.

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy

Disney

Trade Desk

They might not be available so cheaply for too much longer.

3 Unstoppable Stocks You Can Buy Now for Less Than $100

The Clock Is Ticking to Buy This Game-Changing Stock at a Discount

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.

Novocure to Report Third Quarter 2022 Financial Results

NovoCure faces a host of growth options along two key vectors: new geographies and other cancer applications. Despite short-term de-growth in active patients, long-term tailwinds to market share justify the company's superior multiple expansion.

NovoCure: See Past Market Myopia And Buy The Dip

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Novocure's U.S. CNS business, and is intended to renew focus on growth in Novocure's glioblastoma (GBM) business. Frank Leonard, who served as Novocure's Chief Development Officer since 2020, is named President, CNS Cancers U.S., effective September

Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business

NovoCure has maintained a large amount of institutional investors since IPO in 2015, and has nearly 78% of shares held by institutions today. Insider Ownership is high as well at 14% indicating employees have conviction in the long-term outlook of the company.

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Motley Fool contributor Brian Orelli shares why he loves this stock

Why I Own Novocure Stock (NVCR)

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure's leadership team to tour the company's U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure's groundbreaking work to extend patient survival in some of the most aggressive forms of cancer. Following the tour, Sen. Hassan met with Novocure employees to answer questions and provide an update on her work in Washington. In her remarks, Sen. Hassan spoke about the

Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility

Rexford Industrial Realty

T-Mobile US

It's not too late to snatch up some great stocks at good prices.

5 Top Stocks for August

Novocure Ltd (NASDAQ:NVCR ) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg - VP, IR William Doyle - Executive Chairman Ashley Cordova - CFO Asaf Danziger - President, CEO & Director Uri Weinberg - Chief Science Officer Pritesh Shah - Chief Commercial Officer Conference Call Participants Cory Kasimov - JPMorgan Chase & Co. Jason Bednar - Piper Sandler & Co. Gregory Fraser - Truist Securities Emily Bodnar - H.C. Wainwright & Co. Jason Wittes - Loop Capital Markets Operator Good day, and welcome to the NovoCure Q2 2022 Earnings Call.

Novocure Ltd (NVCR) CEO Asaf Danziger on Q2 2022 Results - Earnings Call Transcript

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “The second quarter was a period of solid progress, further solidifying the fundamentals of our business,” said William Doyle, Novocure's Executive Chairman. “We gen

Novocure Reports Second Quarter 2022 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields). The AACR is the world's first and largest professional organization dedicated to advancing ca

Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Axsome Therapeutics

Maravai LifeSciences Holdings

Each of these stocks is ready for a rebound.

3 Beaten-Down Stocks That Could Soar in the Second Half of 2022

These stocks appear to have good chances of delivering solid gains by year-end.

3 Growth Stocks That Could Make You Richer in the Second Half of 2022

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure's management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2022, at 8 a.m. EDT on Thursday, July 28, 2022. To access the conference call by phone, use the following registration link, and dial-in de

Novocure to Report Second Quarter 2022 Financial Results

NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in NovoCure (NVCR): Can Its 8% Jump Turn into More Strength?

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields) together with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, for the first-line treatment of locally advanced or metastatic intrathoracic non-small

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

The broader stock market sell-off is pulling Novocure down.

Why Novocure Stock Is Plunging This Week

Ginkgo Bioworks Holdings

Novavax

Huge rebounds could be in store for these beaten-down stocks.

3 Stocks Down 50% or More That You Can Buy Right Now

ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NVCR #gastriccancer--Novocure and Zai Lab announced that the EF-31 phase 2 pilot study met its primary endpoint as a first-line treatment of gastric cancer.

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

MercadoLibre

Teladoc

A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.

3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure has entered into a clinical trial collaboration agreement with MSD to study the use of Tumor Treating Fields concomitant with MSD's KEYTRUDA.

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma

Align Technology

PayPal

Their long-term prospects look great -- even if their current stock charts don't.

Nasdaq Bear Market: 3 Great Stocks to Buy That Are Down 50% or More

NovoCure's growth has stalled as their GBM market share has gone to 35%-40%, but GBM still offers several additional growth opportunities. Then there are the 4 P3 trials which, if successful, could add additional cancer treatments and dramatically expand the TAM.

News for Novocure Stock (NVCR)